Search for content, post, videos

Aqilion appoints new Head of Preclinical Development

Anneli Hällgren

Anneli Hällgren has been appointed the new head of preclinical development, including regulatory safety studies.

Hällgren has worked for the past ten years as a consultant in preclinical drug discovery and will now join the Aqilion team on a part-time basis.

“I’m convinced that Anneli Hällgren’s expertise will be extremely valuable for Aqilion’s continued preparations for clinical trials in the company’s phase-1-ready anti-inflammatory program Regulus, as well as the continued preclinical development in the Alnitak program. My colleagues and I are excited about the opportunity to work with Anneli and to benefit from her drive and experience in our operational team,” says Sarah Fredriksson, CEO of Aqilion.

Anneli Hällgren

Anneli Hällgren holds a PhD in physiology from Uppsala University, Sweden, and has more than 20 years of experience in research and development projects with a focus on a variety of indications and disease areas, including inflammatory and autoimmune conditions. Her career began at AstraZeneca, where she worked as a safety pharmacologist and preclinical project manager. Since then, she has held leading positions at companies such as KaroBio, Biolipox and Melacure Therapeutics.

Anneli has also belonged to the management of a major EU-funded platform project and has been involved in starting new biotech companies.

Photo Anneli Hällgren: Aqilion